Cim Investment Management Inc. Has $2.37 Million Stock Position in Boston Scientific Corporation $BSX

Cim Investment Management Inc. boosted its holdings in Boston Scientific Corporation (NYSE:BSX) by 99.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 24,092 shares of the medical equipment provider’s stock after buying an additional 12,023 shares during the period. Cim Investment Management Inc.’s holdings in Boston Scientific were worth $2,369,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. B. Riley Wealth Advisors Inc. bought a new position in Boston Scientific during the second quarter worth $1,282,000. Advisory Services Network LLC grew its position in Boston Scientific by 9.0% in the 2nd quarter. Advisory Services Network LLC now owns 34,096 shares of the medical equipment provider’s stock worth $3,577,000 after purchasing an additional 2,812 shares during the last quarter. Anchor Investment Management LLC increased its holdings in shares of Boston Scientific by 8.8% during the 2nd quarter. Anchor Investment Management LLC now owns 8,314 shares of the medical equipment provider’s stock worth $893,000 after purchasing an additional 669 shares during the period. State of Wyoming raised its position in shares of Boston Scientific by 116.8% during the second quarter. State of Wyoming now owns 4,266 shares of the medical equipment provider’s stock valued at $458,000 after buying an additional 2,298 shares during the last quarter. Finally, L1 Capital Pty Ltd bought a new stake in shares of Boston Scientific in the second quarter valued at about $129,000. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Performance

Boston Scientific stock opened at $92.58 on Friday. The firm has a market capitalization of $137.24 billion, a P/E ratio of 49.51, a P/E/G ratio of 1.86 and a beta of 0.67. The stock has a fifty day moving average price of $98.85 and a two-hundred day moving average price of $101.61. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In related news, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This trade represents a 34.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 143,095 shares of company stock valued at $14,228,950. Corporate insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on BSX shares. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and upped their price target for the company from $118.00 to $125.00 in a report on Monday, September 8th. Robert W. Baird boosted their price objective on Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Truist Financial raised their target price on Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Wells Fargo & Company lifted their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Finally, BTIG Research restated a “buy” rating and issued a $132.00 price objective on shares of Boston Scientific in a research note on Friday, November 21st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $124.43.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.